Sana Biotechnology (SANA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
16 figures withheld by our checks. Each blank figure names its reason.
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+52.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲8.5%
−244.2
FY21→FY25CAGR —
Free cash flow ($M)▲43.6%
−144.8
FY21→FY25CAGR —
Diluted EPS▲17.2%
−0.96
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+52.2%
166.4mn → 253.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$938.0K
−97.2% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 111,358.0 | 161,412.0 | 206,792.0 | 212,828.0 | 201,003.0 | 306,499.0 | ▼21.9% | −14.8% |
Selling, general & admin | 45,369.0 | 44,296.0 | 64,040.0 | 73,299.0 | 71,561.0 | 50,410.0 | ▼30.8% | −3.2% |
Total operating expenses | 156,727.0 | 250,319.0 | 272,723.0 | 293,141.0 | 272,564.0 | 356,909.0 | ▼8.2% | −8.5% |
Operating incomefeeds ROC rank | −156,727.0 | −250,319.0 | −272,723.0 | −293,141.0 | −272,564.0 | −356,909.0 | ▲8.2% | — |
Other income, net | 5,153.0 | 3,848.0 | 5,964.0 | 9,886.0 | 3,088.0 | 981.0 | — | — |
Pretax income | −151,574.0 | −246,471.0 | −266,759.0 | −283,255.0 | −269,476.0 | −355,928.0 | ▲7.6% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −149,269.0 | −244,166.0 | −266,759.0 | −283,255.0 | −269,476.0 | −355,928.0 | ▲8.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.52 | −0.96 | −1.16 | −1.46 | −1.43 | −2.14 | ▲17.2% | — |
Diluted shares (mn) | 308.79 | 253.23 | 230.89 | 194.54 | 188.34 | 166.43 | ▲9.7% | +11.1% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

